Skip to main content

Clinical trial AG013-ODOM-201

A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy

Cancers
Organ Tête et Cou
Trial status Trial closed
Investigator
Trial type
Interventionnal with IMP
Phase Trial phase 2
Academic trial Non
Sponsor Oragenics
EudraCT Identifier 2016-004161-68
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03234465
Inclusion criteria No prior gene therapy
Last update